ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2996

Evaluation of Systemic Sclerosis Risk Genes in the Turkish Population

Javier Martín1, Francisco David Carmona2, Tamara Fernández-Aranguren1, Alberto Serrano-Fernández3, Ahmet Mesut Onat4, Gema Robledo5, Enrique Raya6, Haner Direskeneli7, Amr H. Sawalha8 and Sule Yavuz9, 1Instituto de Parasitología y Biomedicina López- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 3Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla, Spain, 4İnternal Medicine Division of Rheumatology, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey, 5Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 6Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, 7Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 8Division of Rheumatology, University of Michigan, Ann Arbor, MI, 9Rheumatology, Istanbul Bilim University, Faculty of Medicine,Department of Rheumatology, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: genetics and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The use of high-throughput genotyping platforms has allowed a better understanding of the genetic background underlying systemic sclerosis (SSc). Sixteen non-HLA genes have been consistently associated with SSc at the genome-wide level of significance, with IRF5, STAT4, CD247, DNASE1L3, IL12A and ATG5 representing the top signals in the two most powered large-scale analyses on SSc performed to date (a genome-wide association study and an Immunochip study in Europeans). We aimed to evaluate for the first time the possible role of the above mentioned genes in SSc susceptibility in the Turkish population.

Methods: We genotyped a total of 355 SSc patients and 718 unrelated healthy controls from Turkey for the SSc-associated lead genetic variants IRF5 rs10488631, STAT4 rs3821236, CD247 rs2056626, DNASE1L3 rs35677470, IL12A rs77583790, and ATG5 rs9373839. The genotyping of the whole SSc group and part of the control group (219 samples) was performed by TaqMan assays, whereas the remaining control data (499 samples) was obtained using the Immunochip platform. To test for association, we compared the minor allele frequencies of every polymorphism between cases and controls by performing 2×2 contingency tables and x2 tests.

Results: The overall analysis evidenced statistically significant associations of the global SSc with IRF5 (P=1.48E-05, OR=1.76, CI 95%=1.36-2.27) and CD247 (P=2.20E-03, OR=0.75, CI 95%=0.62-0.90). Trends of association were also suggested for STAT4 (P=0.066, OR=1.21, CI 95%=0.99-1.48), IL12A (P=0.080, OR=4.06, Ci 95%=0.74-22.23), and DNASE1L3 (P=0.100, OR=1.41, CI 95%=0.93-2.11). Interestingly, the subphenotype analysis showed subtype- and autoantibody-specific associations, that is, CD247 was specifically associated with the diffuse form of the disease (diffuse SSc vs controls: P=4.91E-04, OR=0.64, CI 95%=0.49-0.82; diffuse SSc vs limited SSc: P=0.065, OR=0.75, CI 95%=0.55-1.02), and IRF5 with the presence of anti-topoisomerase autoantibodies (ATA+ SSc vs controls: P= 8.84E-08, OR=2.28, CI 95%=1.68-3.11; ATA+ SSc vs ATA- SSc: P=8.43E-03, OR=1.70, CI 95%=1.14-2.52).

Conclusion: We were able to replicate the associations of IRF5 rs10488631 and CD247 rs2056626 with SSc in the Turkish population, thus confirming the relevant role that these genes may have in the pathophysiology of this disease.


Disclosure: J. Martín, None; F. D. Carmona, None; T. Fernández-Aranguren, None; A. Serrano-Fernández, None; A. M. Onat, None; G. Robledo, None; E. Raya, None; H. Direskeneli, None; A. H. Sawalha, None; S. Yavuz, None.

To cite this abstract in AMA style:

Martín J, Carmona FD, Fernández-Aranguren T, Serrano-Fernández A, Onat AM, Robledo G, Raya E, Direskeneli H, Sawalha AH, Yavuz S. Evaluation of Systemic Sclerosis Risk Genes in the Turkish Population [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-systemic-sclerosis-risk-genes-in-the-turkish-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-systemic-sclerosis-risk-genes-in-the-turkish-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology